ECSP21034281A - Compuesto de 1,3,4-oxadiazolona y fármaco - Google Patents
Compuesto de 1,3,4-oxadiazolona y fármacoInfo
- Publication number
- ECSP21034281A ECSP21034281A ECSENADI202134281A ECDI202134281A ECSP21034281A EC SP21034281 A ECSP21034281 A EC SP21034281A EC SENADI202134281 A ECSENADI202134281 A EC SENADI202134281A EC DI202134281 A ECDI202134281 A EC DI202134281A EC SP21034281 A ECSP21034281 A EC SP21034281A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- present
- oxadiazolone
- inhibitory activity
- compound according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 2
- WTSXVIMLKCKWIW-UHFFFAOYSA-N 3h-1,3,4-oxadiazol-2-one Chemical compound O=C1NN=CO1 WTSXVIMLKCKWIW-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- -1 1,3,4-oxadiazolone compound Chemical class 0.000 abstract 1
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
El propósito de la presente invención es proporcionar un compuesto que tenga actividad inhibidora de PIM. Los ejemplos del compuesto de acuerdo con la presente invención incluyen un compuesto de 1,3,4-oxadiazolona representado por la fórmula [1], y sus sales y solvatos farmacéuticamente aceptables. El compuesto de acuerdo con la presente invención tiene actividad inhibidora de PIM. Debido a que tiene la actividad inhibidora de PIM, el compuesto de acuerdo con la presente invención es útil como un agente terapéutico para lupus eritematoso sistémico, nefritis lúpica, etc.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018214950 | 2018-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP21034281A true ECSP21034281A (es) | 2021-06-30 |
Family
ID=70731909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202134281A ECSP21034281A (es) | 2018-11-15 | 2021-05-14 | Compuesto de 1,3,4-oxadiazolona y fármaco |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220024921A1 (es) |
EP (1) | EP3882239A4 (es) |
JP (1) | JP7434172B2 (es) |
KR (1) | KR20210091767A (es) |
CN (1) | CN113302184A (es) |
AU (1) | AU2019381493A1 (es) |
BR (1) | BR112021009198A2 (es) |
CA (1) | CA3117550A1 (es) |
CL (1) | CL2021001275A1 (es) |
CO (1) | CO2021007442A2 (es) |
EA (1) | EA202191349A1 (es) |
EC (1) | ECSP21034281A (es) |
IL (1) | IL282999A (es) |
MA (1) | MA54243A (es) |
MX (1) | MX2021005566A (es) |
PE (1) | PE20211283A1 (es) |
PH (1) | PH12021551103A1 (es) |
SG (1) | SG11202104371XA (es) |
WO (1) | WO2020100959A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117285459B (zh) * | 2023-11-24 | 2024-02-27 | 上海美迪西生物医药股份有限公司 | 一种小分子激酶抑制剂化合物的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01139581A (ja) * | 1987-08-20 | 1989-06-01 | Nissan Chem Ind Ltd | テトラヒドロフタルイミド誘導体、その製法および除草剤 |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
US20090105221A1 (en) | 2004-09-29 | 2009-04-23 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
CN101084191A (zh) | 2004-12-22 | 2007-12-05 | 默克公司 | 用于制备取代哌啶类化合物的方法 |
JP2011515337A (ja) | 2008-02-29 | 2011-05-19 | サイレーン ファーマシューティカルズ, インコーポレイテッド | プロテインキナーゼモジュレーター |
GB0813740D0 (en) | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
EP2796456A1 (en) | 2010-12-09 | 2014-10-29 | Amgen Inc. | Bicyclic compounds as Pim inhibitors |
AU2012230890A1 (en) * | 2011-03-22 | 2013-09-26 | Amgen Inc. | Azole compounds as Pim inhibitors |
WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
RU2014151009A (ru) | 2012-06-07 | 2016-08-10 | Ф. Хоффманн-Ля Рош Аг | Пиразолопиримидоновые и пиразолопиридоновые ингибиторы танкиразы |
GB201814151D0 (en) * | 2018-08-31 | 2018-10-17 | Ucl Business Plc | Compounds |
-
2019
- 2019-11-14 EA EA202191349A patent/EA202191349A1/ru unknown
- 2019-11-14 AU AU2019381493A patent/AU2019381493A1/en active Pending
- 2019-11-14 EP EP19883405.3A patent/EP3882239A4/en active Pending
- 2019-11-14 WO PCT/JP2019/044615 patent/WO2020100959A1/ja active Application Filing
- 2019-11-14 SG SG11202104371XA patent/SG11202104371XA/en unknown
- 2019-11-14 BR BR112021009198-0A patent/BR112021009198A2/pt unknown
- 2019-11-14 JP JP2020556150A patent/JP7434172B2/ja active Active
- 2019-11-14 KR KR1020217017903A patent/KR20210091767A/ko unknown
- 2019-11-14 PE PE2021000693A patent/PE20211283A1/es unknown
- 2019-11-14 MA MA054243A patent/MA54243A/fr unknown
- 2019-11-14 CA CA3117550A patent/CA3117550A1/en active Pending
- 2019-11-14 US US17/293,929 patent/US20220024921A1/en active Pending
- 2019-11-14 CN CN201980089037.7A patent/CN113302184A/zh active Pending
- 2019-11-14 MX MX2021005566A patent/MX2021005566A/es unknown
-
2021
- 2021-05-06 IL IL282999A patent/IL282999A/en unknown
- 2021-05-14 CL CL2021001275A patent/CL2021001275A1/es unknown
- 2021-05-14 PH PH12021551103A patent/PH12021551103A1/en unknown
- 2021-05-14 EC ECSENADI202134281A patent/ECSP21034281A/es unknown
- 2021-06-08 CO CONC2021/0007442A patent/CO2021007442A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021005566A (es) | 2021-07-15 |
PH12021551103A1 (en) | 2021-11-22 |
EP3882239A4 (en) | 2022-08-10 |
EA202191349A1 (ru) | 2021-08-10 |
JP7434172B2 (ja) | 2024-02-20 |
CO2021007442A2 (es) | 2021-06-21 |
IL282999A (en) | 2021-06-30 |
SG11202104371XA (en) | 2021-05-28 |
WO2020100959A1 (ja) | 2020-05-22 |
MA54243A (fr) | 2021-09-22 |
PE20211283A1 (es) | 2021-07-19 |
JPWO2020100959A1 (ja) | 2021-10-07 |
CA3117550A1 (en) | 2020-05-22 |
KR20210091767A (ko) | 2021-07-22 |
EP3882239A1 (en) | 2021-09-22 |
CN113302184A (zh) | 2021-08-24 |
BR112021009198A2 (pt) | 2021-08-03 |
US20220024921A1 (en) | 2022-01-27 |
AU2019381493A1 (en) | 2021-06-03 |
TW202031649A (zh) | 2020-09-01 |
CL2021001275A1 (es) | 2021-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2019005552A2 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
UY35612A (es) | Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio | |
CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
CO2018012485A2 (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos | |
CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
TR201906325T4 (tr) | Tetrazolon sübstitüeli dihidropiridinon MGAT2 inhibitörleri. | |
CO2022001814A2 (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
CL2021002480A1 (es) | Agonistas compuestos macrocíclicos como de sting | |
BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
ECSP20079861A (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
BR112017015744A2 (pt) | composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas | |
CO2021007442A2 (es) | Compuesto de 1,3,4-oxadiazolona y fármaco | |
CO2022008209A2 (es) | Compuesto que funciona como inhibidor de la quinasa del receptor de pdgf y composición | |
BR112022012368A2 (pt) | Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2 | |
CO2020001375A2 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico | |
BR112021016912A2 (pt) | Composto de benzoindazolona e intermediário do mesmo | |
SV2017005527A (es) | Agente terapéutico para disfunción del lóbulo frontal | |
MX2019002104A (es) | Compuesto de 3-piridiloxifenildihidrouracilo y su uso. |